Effects on the Uterus

Saameli, K

doi:10.1007/978-3-642-66775-6_4

Cited by 15 publications

(9 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could explain the insensitivity to the second dose of 0.2 mg methylergometrine in postpartum uteri lasting 3 h, measured by external tocography as reported in 1959 [18] and observed in our experiments even 24 h after oral administration of 0.5 mg methylergometrine, Methylergometrine probably blocks a-receptors in the inner layer, specifically affecting the basal tone of this layer [19][20][21].…”

Section: Discussionsupporting

confidence: 78%

Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus

Groot¹,

Dongen²,

Vree³

et al. 1995

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Objective: To study the pharmacodynamic and pharmacokinetic properties of oral and intravenous methylergometrine upon uterine motility during menstruation. Study-design: Intra-uterine pressure was measured in six volunteers with a fluid-filled spongetipped catheter during menstruation. Methylergometrine was given orally (0.5 mg) or intravenously (0.2 mg) in a cross-over design. Results: After intravenous administration, a fast increase of the frequency of uterine contractions and basal tone occurred with a decrease of amplitude, lasting at least 30 min. Oral administration had a late and less marked effect on uterine motility. An intra venous dose administered 24 h after an oral dose had no effect on uterine motility. Pharmacokinetic data, such as the maximum plasma concentration (Cmax), the time at which Cmax is reached (tmax) and the half-life of absorption a^so demonstrated large individual variations after oral administration. Conclusion: Oral administration of methylergometrine had an unpredictable and late effect on uterine motility on the menstruating uterus, probably due to an unpredictable bioavailability, in contrast with the fast and predictable effect after intravenous administration.

show abstract

Section: Discussionsupporting

confidence: 78%

Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus

Groot¹,

Dongen²,

Vree³

et al. 1995

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

show abstract

“…While extensive experimental and clinical experience supports the use of ergot alkaloids like methylergometrine for stimulation of myometrial activity in the early puerperium, the risk of uterine hypertonus has prevented the use of this drug in late pregnancy and labour (124).…”

Section: A D a Obstet Gynecol Scand Suppl121mentioning

confidence: 99%

Calcium entry blockade as a therapeutic principle in the female urogenital tract

Forman

1984

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

“…Therefore we chose to induce contractions by the ergot alkaloid ergometrin which is known to be a powerful uterine stimulant (cf. Saameli,9). When comparing the resultant changes in frequency and amplitude after 3 h in the methylergometrine treated experiments versus the spontaneously contracting preparations, we were unable to detect any significant differences.…”

Section: Discussionmentioning

confidence: 81%

“…Therefore, experiments with the non-specific a-blocker phentolamine were added and these again did not show any significant changes. The experiment with phentolarnine seems to have special relevance in our study, since in a large number of preparations uterine activity was induced with ergornetrine, which is a partial alpha against (9). It therefore seems very unlikely that a-blockade is involved in the slight amplitude-reducing effect of labetalol, either in our in vitro experiments or in vivo, where a-blocking potency is lower than in vitro (14).…”

Section: Frequency (Contractions/h) and Amplitude (G) Of Human Utermentioning

confidence: 85%

The Effect of Labetalol on Contractility of Human Myometrial Preparations

Thulesius

Lunell

Ibrahim

et al. 1987

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Because of results in animal experiments which demonstrated a partial beta 2-adrenoceptor activity of labetalol on rat uterine smooth muscle the present study was conducted in human preparations. The following results were obtained: 1. Rhythmic uterine contractions with a defined steady-state amplitude and frequency were elicited spontaneously and after methylergometrine. 2. Labetalol reduced amplitude of contractions dose-dependently after 3 h of incubation. Frequency was unaffected. 3. The tocolytic effect of labetalol is apparent only at high concentrations, above those used in the treatment of hypertension. 4. Neither beta 2-specific adrenoceptor blockade with ICI 118,551 nor alpha-blockade with phentolamine changed amplitude of contraction, either alone or in combination with labetalol. 5. Labetalol has little tocolytic effect on human myometrium in vitro. This effect is unrelated to alpha- or beta-antagonism, but seems to depend on a direct smooth muscle depressant effect. In conclusion, from the present in vitro experiments using human myometrial preparations, it seems unlikely that labetalol would interfere with the normal process of labor when used for the treatment of pregnancy hypertension.

show abstract

Effects on the Uterus

Cited by 15 publications

References 67 publications

Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus

Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus

Calcium entry blockade as a therapeutic principle in the female urogenital tract

The Effect of Labetalol on Contractility of Human Myometrial Preparations

Contact Info

Product

Resources

About